
Opinion|Videos|April 14, 2025
Exploring Updates From KEYNOTE-799 at ELCC 2025
Panelists discuss how KEYNOTE-799 provides updated data on safety, toxicity, positive response rates, and median survival rates for both squamous and nonsquamous non–small cell lung cancer treatments.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































